RecruitingPhase 2NCT06654011

IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial

Studying Adenocarcinoma of the cervix uteri

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Principal Investigator
Peng Wu, Ph.D
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Intervention
IN10018(drug)
Enrollment
25 enrolled
Eligibility
18-75 years · FEMALE
Timeline
20252026

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06654011 on ClinicalTrials.gov

Other trials for Adenocarcinoma of the cervix uteri

Additional recruiting or active studies for the same condition.

See all trials for Adenocarcinoma of the cervix uteri

← Back to all trials